Welcome to our dedicated page for Lifevantage SEC filings (Ticker: LFVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching for LifeVantage Corp’s latest consultant counts or product-line revenue without wading through dense text? Investors typically arrive here asking, “Where can I find LifeVantage’s quarterly earnings report 10-Q filing?” or “How do I track LifeVantage insider trading Form 4 transactions in real time?” This page bundles every SEC disclosure so you no longer jump between scattered EDGAR links.
Stock Titan’s AI reads each LifeVantage 8-K, 10-Q, and 10-K the moment it posts, then delivers plain-English summaries that flag shifts in independent-consultant enrollment, inventory risk and regulatory updates around nutrigenomic claims. Instead of skimming 200-plus pages, you’ll see the numbers that shape margins—net sales by product family, commission expense trends and emerging compliance issues—explained simply.
Use our quick-access tiles to drill into:
- Annual report 10-K simplified – pick out segment revenue, R&D on nutrigenomics and direct-sales compensation disclosures in minutes.
- Quarterly earnings report 10-Q – monitor consultant turnover, inventory levels and cash flow each quarter with AI-annotated highlights.
- Form 4 insider transactions – real-time alerts on LifeVantage executive stock moves so you can spot buying or selling trends fast.
- 8-K material events explained – leadership changes, product-safety notices or distributor policy updates distilled into key takeaways.
- Proxy statement executive compensation – understand how bonuses tie to enrolment growth and nutrigenomic product launches.
Whether you’re comparing quarters, dissecting compensation plans, or simply trying to “understand LifeVantage SEC documents with AI,” this hub keeps every filing current and comprehensible. Save hours, gain clarity, and turn regulatory disclosures into actionable insight.
Alissa Neufeld, General Counsel of Lifevantage Corp (LFVN), received equity awards on 08/26/2025. The Form 4 shows an award of 9,036 stock units and 13,554 Performance Restricted Stock Units (PRSUs). After the grant, Ms. Neufeld beneficially owns 100,605 shares of common stock and 13,554 PRSU equivalents. The stock units vest with 5/12 of the award on September 10, 2026 and the remainder in equal installments on the tenth day of the third month of each of seven subsequent calendar quarters. The PRSUs vest only if performance targets are met (target payout shown); upon maximum performance the award may pay up to 200% of target, with vested portions scheduled 34% on Sept 10, 2026, 33% on Sept 10, 2027, and 33% on Sept 10, 2028.
Lifevantage Corp (LFVN) reported a Form 4 showing equity awards to Julie Boyster, the company's Chief Marketing Officer. The filing discloses a non‑derivative grant of 13,102 common stock units on 08/26/2025, increasing her directly held common shares to 128,316. The filing also shows 19,654 Performance Restricted Stock Units (PRSUs) granted the same date, representing rights to receive that many shares if performance targets are met; the PRSUs count as 19,654 underlying shares for beneficial ownership. The stock units vest over time subject to continued service: 5/12 of the stock unit award vests on September 10, 2026, with the remainder in equal installments across seven calendar quarters thereafter. The PRSUs vest only to the extent financial performance criteria are achieved and, if earned, vest in three tranches on September 10, 2026, 2027 and 2028 (34%, 33%, 33%). The Form 4 was signed by a power of attorney on 08/28/2025.
Lifevantage Corp (LFVN) reporting person Steven R. Fife, President and CEO and a director, received non‑derivative and derivative equity awards on 08/26/2025. He was granted 48,193 stock units that represent rights to receive common stock and will hold 659,500 shares beneficially following the grant. He also received 72,289 Performance Restricted Stock Units (PRSUs) at target, with each PRSU representing one share at $0 exercise price; PRSU vesting is contingent on performance and continued service.
The stock units vest partly on September 10, 2026 and then in installments across seven quarters; PRSU vesting, if earned, vests 34% on September 10, 2026, 33% on September 10, 2027 and 33% on September 10, 2028. The Form 4 was signed by a power of attorney on 08/28/2025.
Lifevantage Corp (LFVN) reporting person Kristen Cunningham, Chief Sales Officer, received equity awards on 08/26/2025. The filing shows a grant of 12,349 stock units (each convertible to one share) and 18,524 performance restricted stock units (PRSUs) representing target-level awards. Following the transactions, Cunningham beneficially owns 116,351 shares and 18,524 PRSU-equivalent shares reported as direct ownership. The stock units vest over time subject to continued service, and the PRSUs vest only if specified performance criteria are met, with potential payout up to 200% of target.
Lifevantage Corp (LFVN) Chief Financial Officer Carl Aure received equity awards on 08/26/2025. The Form 4 reports an award of 10,241 stock units that represent rights to receive common shares and 15,361 Performance Restricted Stock Units (PRSUs) that are earned based on specified financial performance criteria. After the reported transactions, the filing shows 143,544 shares beneficially owned and 15,361 derivative shares from PRSUs. The stock units vest over time with a schedule beginning September 10, 2026, and the PRSUs vest contingent on performance and continued service with vesting dates in 2026–2028. The form was signed by power of attorney on 08/28/2025.
FAQ
What is the current stock price of Lifevantage (LFVN)?
What is the market cap of Lifevantage (LFVN)?
